10X Genomics Hits New 52-Week High of $65.46, Up 193.6% Year-Over-Year

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 65.46 on August 21, 2026. This achievement marks a remarkable 193.6% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 20.47% during the same period. The company's market capitalization stands at approximately USD 2,489 million, reflecting its position within the small-cap category. Despite being loss-making, 10X Genomics has demonstrated resilience in the market, as indicated by its substantial price appreciation from a 52-week low of USD 11.16. Key financial metrics reveal a price-to-book ratio of 3.13, while the company currently does not offer a dividend yield. The debt-to-equity ratio is reported at -0.64, and the return on equity stands at -10.80%. This recent price movement underscores the dynamic nature of 10X Genomics' stock performance within the biotechnology landscape.